Is Synopsys (SNPS) Overvalued or Undervalued? A Complete Valuation Analysis 2026

The short answer

Short answer: Synopsys looks overvalued at current levels. Compared with the recent share price of $505.19, the current DCF output near $252.24 suggests Synopsys is about 100.3% overvalued on these cash flow assumptions. Synopsys is being valued in the context of a business with gross margin near 75.1%, which helps show what kind of operating model investors are paying for. That leaves Synopsys looking rich unless the next leg of earnings or cash flow growth arrives fast enough to justify the current price.

Why valuing this kind of technology company is more complex than it looks

Synopsys operates in Software - Infrastructure. Companies in this part of the market are usually valued on a mix of current earnings, expected growth, margin durability, and cash generation.

The reason this matters is simple. Two companies can show similar headline multiples and still deserve very different valuations because their margins, cash conversion, and growth durability are not the same.

The 5 key metrics applied to Synopsys

A single ratio rarely tells the whole story. This framework starts with trailing P/E, forward P/E, PEG, EV/EBITDA, and price to sales, then keeps only the metrics that are present and usable for this company.

Trailing P/E

Trailing P/E compares the current share price with the last twelve months of earnings. For Synopsys, the current reading is 62.1x. Shows what the market is paying for Synopsys's recent earnings.

Forward P/E

Forward P/E uses expected earnings instead of trailing earnings. For Synopsys, the current reading is 164.9x. Shows how the market is valuing Synopsys's expected earnings.

EV/EBITDA

EV/EBITDA compares enterprise value with operating profit before depreciation and amortization. For Synopsys, the current reading is 31.9x. Adds a capital structure aware check on operating valuation.

Price to sales

Price to sales compares market value with revenue. For Synopsys, the current reading is 12.1x. Useful when revenue mix, margins, or future scaling matter as much as near term earnings.

Free cash flow yield

Free cash flow yield compares free cash flow with market value. For Synopsys, the current reading is 2.4%. Shows how much cash Synopsys is generating relative to its market value.

Metric	Current value	What it suggests
Trailing P/E	62.1x	Shows what the market is paying for Synopsys's recent earnings.
Forward P/E	164.9x	Shows how the market is valuing Synopsys's expected earnings.
EV/EBITDA	31.9x	Adds a capital structure aware check on operating valuation.
Price to sales	12.1x	Useful when revenue mix, margins, or future scaling matter as much as near term earnings.
Free cash flow yield	2.4%	Shows how much cash Synopsys is generating relative to its market value.
Gross margin	75.1%	Shows how much of Synopsys's revenue remains after direct costs.
Revenue growth	15.1%	Shows whether Synopsys's top line is still expanding.

The table is a snapshot of the current setup. It is meant to frame the valuation question, not replace the company specific analysis below.

Synopsys's valuation breakdown

As of Q2 2026, Synopsys traded near $505.19 with a market value near $96.78B.

Metric	Current value	What it suggests
Trailing P/E	62.1x	Shows what the market is paying for Synopsys's recent earnings.
Forward P/E	164.9x	Shows how the market is valuing Synopsys's expected earnings.
EV/EBITDA	31.9x	Adds a capital structure aware check on operating valuation.
Price to sales	12.1x	Useful when revenue mix, margins, or future scaling matter as much as near term earnings.
Free cash flow yield	2.4%	Shows how much cash Synopsys is generating relative to its market value.
Gross margin	75.1%	Shows how much of Synopsys's revenue remains after direct costs.
Revenue growth	15.1%	Shows whether Synopsys's top line is still expanding.

Metrics move with the market and with each earnings update. If a field is missing or stale, it is intentionally left out here rather than guessed.

What the numbers tell us

The first thing to notice with Synopsys is the gap between trailing and forward earnings valuation. Trailing P/E is near 62.1x while forward P/E is near 164.9x, which tells you the market is already underwriting a specific earnings path.

Synopsys's forward P/E is not offering much relief versus the trailing multiple, so the market may still be paying up before the earnings improvement is fully visible.
Synopsys's price to sales multiple near 12.1x needs to be read beside revenue growth near 15.1%, because rich revenue multiples only hold up when growth quality stays intact.
Synopsys's gross margin near 75.1% helps explain whether the market is dealing with a commodity style business or a business with stronger pricing power and business mix.

Synopsys's competitive position

provides electronic design automation software products used to design and test integrated circuits.

What would make Synopsys look cheaper or more expensive?

What would make it look cheaper

Synopsys would look cheaper if the business kept growing while valuation multiples moved lower.
Synopsys would also look more attractive if cash generation improved without the market price rising at the same pace.

What would make it look expensive

Synopsys would look expensive if earnings or revenue expectations softened while the current multiple stayed elevated.
Synopsys would also look expensive if margins weakened but the stock kept the same quality premium.

Technology valuation context

Synopsys operates in Software - Infrastructure. Companies in this part of the market are usually valued on a mix of current earnings, expected growth, margin durability, and cash generation.

The verdict

Synopsys looks priced for a very strong execution path from here. The stock can still work, but future earnings and cash flow need to validate the premium already in the shares. With forward P/E near 164.9x, the market is already making a judgment about the next stage of earnings power.

This is analysis of publicly available market data. It is not financial advice, and it should be read in the context of personal goals, risk tolerance, and time horizon.

Want to run the numbers yourself?

Use TopTier Strategy research tools to review SNPS's live valuation profile, stock page, and related company analysis.

Analyze SNPS on TopTier Strategy View SNPS stock page

Frequently asked questions

Is Synopsys stock overvalued in 2026?

Based on the current research read, Synopsys looks overvalued in 2026. The main drivers in this read are trailing P/E near 62.1x and forward P/E near 164.9x, gross margin near 75.1%, free cash flow yield near 2.4%. Synopsys is being valued in the context of a business with gross margin near 75.1%, which helps show what kind of operating model investors are paying for.

Is Synopsys a good stock to buy right now?

Synopsys can still work for investors who believe the next few years will be stronger than the market already expects, but the current setup leaves less room for disappointment.

What is Synopsys's fair value?

A fair value estimate depends on the mix of earnings, growth, margins, and cash generation rather than on a single published number. For Synopsys, the current read is shaped mainly by trailing P/E near 62.1x and forward P/E near 164.9x, gross margin near 75.1%, free cash flow yield near 2.4%. This article does not publish a stand alone fair value number unless there is a clearly supportable public methodology behind it.

Can you value Synopsys just on P/E?

No. Synopsys needs to be read through multiple valuation lenses, including forward earnings, revenue multiples, cash flow, and business quality.

Where can I analyze SNPS with current data?

Use the TopTier Strategy research platform at toptierstrategy.com/research to review live valuation, profitability, financial health, shareholder returns, and growth data for SNPS.

Data source: TopTier Strategy research platform - toptierstrategy.com/research. Data as of 2026-05-08T00:36:32.337183.